Research
Hormonal
Older anti-obesity medications (Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion) provide modest weight loss (3-10%) but are limited by side effects and lower efficacy compared to newer GLP-1 based therapies.
Older medications like Orlistat, Phentermine/Topiramate, and Naltrexone/Bupropion can help with weight loss (3-10%), but they are less effective than newer GLP-1 drugs. They also have specific side effects like oily stools (Orlistat) or potential mood/cognitive changes (Topiramate/Bupropion). They remain options if newer drugs are inaccessible or unaffordable.
GoodQualifiesHIGH confidence
Orlistat... 10.6 kg weight loss... Phentermine/topiramate... 10.9% weight loss... Naltrexone/bupropion... 6.1% weight loss.
Why this rating
Based on multiple Phase III trials cited (XENDOS, CONQUER, COR-I).
Source
Pharmacologic treatment of obesity
Han Na Jung et al. · Journal of Korean Medical Association · 2022
DOI 10.5124/jkma.2022.65.7.408
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →